link to homepage

Institute of Neuroscience and Medicine
Nuclear Chemistry (INM-5)

Navigation and service

Logo Dual2Pet

Using PET for the Evaluation of Innovative Analgetics with Dual Mode of Action (Dual²PET)

Innovative drugs targeting two modes of action based on one chemical structure are a promising novel therapeutic approach in medicine.

More: Using PET for the Evaluation of Innovative Analgetics with Dual Mode of Action (Dual²PET) …

Logo Pain-Vis


Novel PET tracers provide promising opportunities to study molecular pathological changes associated with peripheral pain and enables to determine its exact location in the body.

More: PAIN-Vis …


Büro / Office

Radiotracer development

The first prerequisite of radiotracer development is an identification of the molecular target. Molecular targets can be specifically addressed by using corresponding lead structures. Usually these lead structures belong to for example enzyme substrates or receptor ligands. More: Radiotracer development …

Spritze mit Vials / Syringe with Vials

Radiopharmaceutical production

The INM-5 produces radiopharmaceuticals for the Positron Emission Tomography (PET) and supplies both FZJ internal institutions and external University clinics (Universities of Aachen, Bonn, Cologne, Münster, among others). More: Radiopharmaceutical production …



PET imaging enables to non-invasively visualize the structure, function, wiring and chemistry of the human brain. More: PET-Imaging …



Usually, all radionuclides applied in molecular imaging have to be produced at an accelerator. More: Cyclotron …

Nuklidkarte / Nuclide chart

Non-standard radionuclides

With the growing impact of PET in clinical diagnosis, besides standard positron emitters the need for novel, non-standard positron emitters, e.g. 64Cu, 73Se, 76Br or 120I, is evident. More: Non-standard radionuclides …



Learn more about PET and MRI More: Information …









Dear visitor,

To make our website suit your needs even more and to give it a more appealing design, we would like you to answer a few short questions.

Answering these questions will take approx. 10 min.

Start now Close window

Thank you for your support!


In case you have already taken part in our survey or in case you have no time to take part now, you can simply close the window by clicking "close".

If you have any questions on the survey, please do not hesitate to contact:


Your Team at Forschungszentrum Jülich


Note: Forschungszentrum Jülich works with the market research institute SKOPOS to anonymously conduct and analyze the survey. SKOPOS complies with the statutory requirements on data protection as well as with the regulations of ADM (Arbeitskreis Deutscher Markt- und Sozialforschungsinstitute e.V.) and ESOMAR (Europäische Gesellschaft für Meinungs- und Marketingforschung). Your data will not be forwarded to third parties.